Point72 (Difc) LTD Protalix Bio Therapeutics, Inc. Transaction History
Point72 (Difc) LTD
- $2.95 Trillion
- Q3 2024
A detailed history of Point72 (Difc) LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 11,600 shares of PLX stock, worth $20,068. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,600Holding current value
$20,068% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.65 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$752,9180.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$646,5990.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$576,3850.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$467,1000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $86.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...